BriMindInvest Logo

Thermo Fisher Scientific Inc. (TMO) Stock Analysis 2026

HealthcareLife Science Tools & Services
$564.75as of 2026-08-04

BriMind AI Score

Proprietary
52
Neutral
Price CAGR
14.2%
1Y Return
+24.0%
Analyst Upside
+9.6%
Rev Growth
10.5%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$601.79+6.6% potential
Bear Case
$419.61
Bull Case
$822.17
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is the world's largest supplier of scientific instruments, reagents, consumables, and services used in life sciences research, pharmaceutical manufacturing, diagnostics, and environmental testing. The company serves academic institutions, pharmaceutical and biotech companies, hospitals, clinical labs, and industrial customers. Thermo Fisher's scale — $44B+ in revenue — and breadth of products (over one million SKUs) create unmatched one-stop-shop purchasing efficiency for customers.

How Thermo Makes Money

Thermo Fisher earns across four segments: Life Science Solutions (research consumables, antibodies, cell biology tools — highest margins), Analytical Instruments (mass spectrometers, electron microscopes, chromatography), Specialty Diagnostics (immunodiagnostics, clinical chemistry), and Laboratory Products & Biopharma Services (contract manufacturing, lab supplies distribution). The company's CDMO (contract development and manufacturing organization) business provides biopharma outsourced manufacturing services.

Thermo Revenue & Profitability Breakdown

This chart shows how Thermo's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$46.34B
Cost of Revenue
-$27.34B
Gross Profit
$18.99B41.0% margin
Operating Expenses
-$10.30B
Operating Income
$8.69B18.8% margin
Tax & Other
-$1.72B
Net Income
$6.97B15.0% margin
Gross Margin
41.0%
Operating Margin
18.8%
Net Margin
15.0%
EBITDA Margin
25.2%

Key Financial Metrics

A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.

Market Cap
$197.88B
Enterprise Value
$180.12B
P/E (Trailing)
30.86
P/E (Forward)
20.88
EV / EBITDA
16.64
Price / Sales
3.54
Price / Book
3.07
Revenue
$46.34B
Revenue Growth
10.5%
Earnings Growth
9.4%
EBITDA
$10.83B
Gross Margin
41.0%
Operating Margin
18.8%
Net Margin
15.0%
Return on Equity
13.5%
Return on Assets
5.1%
Free Cash Flow
$6.24B
Total Cash
$5.95B
Total Debt
$34.26B
Debt / Equity
80.58
Current Ratio
1.55
Quick Ratio
1.01
Beta
0.87
Dividend Yield
0.3%
Payout Ratio
9.7%
Book Value / Share
$139.75

Wall Street Analyst Consensus

Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.

Consensus RatingBuy(27 analysts)
SellStrong Buy
Low Target$450.00-20.3%
Mean Target$629.50+11.5% upside
High Target$767.00+35.8%

Intrinsic Value Estimates for TMO

Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.

DCF Model (10yr)
$346.98
-38.6% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$346.98 – $346.98
Average Estimate
$346.98
Potential Downside
-38.6%

⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

TMO Investment Case: Bull vs Bear

Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

  • Thermo Fisher is indispensable to biopharma R&D — every biotech and pharma company uses Thermo Fisher reagents, instruments, and services at every stage of drug development.
  • Pharma Services (CRO/CDMO) is growing rapidly as biotech companies increasingly outsource manufacturing to Thermo Fisher's industry-leading production network.
  • AI drug discovery is generating more molecules to test, increasing demand for Thermo Fisher's screening tools, analytical instruments, and genomic analysis reagents.
  • Scale advantages in purchasing, distribution, and customer relationships make Thermo Fisher's competitive position in lab supply essentially insurmountable for smaller competitors.

Bear Case (Key Risks)

  • Thermo Fisher experienced a significant COVID-related revenue windfall (COVID testing kits, vaccine manufacturing) that has reversed, creating a multi-year growth comparison challenge.
  • Biopharma customer funding pressures (particularly biotech companies with tight cash) reduce research spending and hit Thermo Fisher's most profitable research tools segment.
  • China life science spending has declined amid US-China tensions and local government budget cuts, reducing a previously significant growth market.
  • Thermo Fisher trades at 20-25x forward earnings — a premium for an instrument/distribution company that requires sustained high growth to justify.

What to Watch: TMO Key Metrics

Core organic revenue growth (ex-COVID)
Pharma Services revenue growth
Life Science Solutions segment margins
China revenue trend
EPS growth vs guidance

TMO Stock — Frequently Asked Questions

Compare TMO with Peers

TMO vs DHRThermo Fisher vs Danaher — Which Life Sciences Tools Gi
TMO vs AThermo Fisher Scientific vs Agilent Technologies — Life
BDX vs TMOBecton Dickinson vs Thermo Fisher — Which Life Sciences
TMO vs WSTThermo Fisher vs West Pharmaceutical — Life Science Gia

Unlock the Full TMO Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
← Back to Home · Browse All Stock Analysis